New hope for stomach cancer patients with hidden HER2 marker
NCT ID NCT04309578
First seen Apr 08, 2026 · Last updated May 16, 2026 · Updated 6 times
Summary
This study tested whether adding the targeted drug trastuzumab to standard chemotherapy could help people with advanced stomach cancer whose tumors test negative for HER2 in tissue but show signs of HER2 in their blood. 28 patients took part. The goal was to see if the combination could shrink tumors and delay cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC OR GASTROESOPHAGEAL JUNCTION(GEJ) ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, Seoul, South Korea
Conditions
Explore the condition pages connected to this study.